Saxenda for weight loss is the brand name for liraglutide 3.0 mg, a daily GLP-1 receptor agonist FDA-approved for chronic weight management. Paired with reduced-calorie eating and exercise, it produces about 5 to 8 percent body weight loss over a year by slowing stomach emptying, increasing fullness, and reducing food cravings.
What Saxenda Is and How It Works
Saxenda contains liraglutide, the same molecule used in the diabetes drug Victoza but at a higher 3.0 mg dose specifically approved for weight management. It belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class — the same family as semaglutide (Ozempic, Wegovy, Rybelsus) and dulaglutide (Trulicity).
The drug mimics the natural gut hormone GLP-1, which is released after eating. Its main weight-related effects include:
- Slowing the rate at which the stomach empties, so meals feel filling for longer
- Acting on appetite centers in the hypothalamus to reduce hunger and food cravings
- Lowering reward signaling around high-calorie foods
- Modestly improving insulin sensitivity and blood glucose control
Who Qualifies for Saxenda
The FDA-approved indications are:
- Adults with a BMI of 30 kg/m² or greater (obesity)
- Adults with a BMI of 27 kg/m² or greater plus a weight-related condition such as type 2 diabetes, high blood pressure, or dyslipidemia
- Adolescents aged 12 to 17 with a body weight above 60 kg and BMI at or above the 95th percentile for age and sex
Saxenda is one of the few GLP-1 weight-loss medications approved for adolescents, which makes it a notable option in pediatric obesity care.
Dosing and Titration Schedule
Saxenda starts low and escalates weekly to reduce GI side effects. Each week’s increase happens only if the previous dose is tolerated.
| Week | Daily Dose | Purpose |
|---|---|---|
| 1 | 0.6 mg | Initial GI tolerance |
| 2 | 1.2 mg | Gradual escalation |
| 3 | 1.8 mg | Same dose as Victoza for diabetes |
| 4 | 2.4 mg | Escalation continues |
| 5+ | 3.0 mg | Maintenance dose for weight loss |
The injection is given subcutaneously into the abdomen, thigh, or upper arm at any time of day — with or without food — but at the same time each day for consistency.
Expected Weight Loss Results
The pivotal SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015) randomized 3,731 adults without diabetes to Saxenda or placebo, both combined with a 500 kcal/day deficit and 150 minutes of weekly exercise. At 56 weeks:
- Mean weight loss was 8.0 percent on Saxenda versus 2.6 percent on placebo
- About 63 percent of Saxenda users lost at least 5 percent of body weight versus 27 percent on placebo
- About 33 percent lost at least 10 percent versus 11 percent on placebo
- Waist circumference, blood pressure, and lipid markers improved alongside weight loss
Progression from prediabetes to type 2 diabetes was reduced by roughly 80 percent in trial participants with prediabetes — a clinically meaningful finding that ties weight loss to longer-term metabolic outcomes. See our explainer on whether prediabetes is reversible for context on this benefit.
Side Effects
Most side effects are gastrointestinal and occur during the first weeks of dose escalation. They typically improve as the body adapts.
| Side Effect | Approximate Frequency | Notes |
|---|---|---|
| Nausea | ~39% | Worst in weeks 1–4; eat smaller, lower-fat meals |
| Diarrhea | ~21% | Usually mild and transient |
| Constipation | ~19% | Hydration and fiber help |
| Vomiting | ~16% | Slow titration if persistent |
| Headache | ~14% | Often related to under-eating |
| Fatigue | ~8% | Improves with adequate calories and sleep |
| Injection site reaction | ~3–5% | Rotate sites; warm pen before injecting |
| Gallbladder events | ~2.5% | Higher risk with rapid weight loss |
| Pancreatitis | <1% | Severe abdominal pain — seek care |
Serious Warnings
- Boxed warning — thyroid C-cell tumors: Liraglutide caused medullary thyroid carcinoma in rodent studies. Human relevance is unclear, but Saxenda is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).
- Pancreatitis: Stop Saxenda and seek medical attention for severe, persistent abdominal pain that radiates to the back.
- Gallbladder disease: Rapid weight loss can precipitate gallstones; report severe upper-right abdominal pain.
- Kidney injury: Dehydration from nausea, vomiting, or diarrhea can stress the kidneys; sip water steadily during dose escalation.
- Hypoglycemia: Risk increases if Saxenda is combined with insulin or a sulfonylurea — dose adjustments may be needed.
- Suicidal thoughts: A small signal of mood changes has been reported with weight-loss medications; report any new low mood or self-harm thoughts.
Saxenda Compared to Other Weight-Loss GLP-1 Drugs
| Drug | Active Ingredient | Schedule | Typical Weight Loss |
|---|---|---|---|
| Saxenda | Liraglutide 3.0 mg | Daily injection | ~5–8% |
| Wegovy | Semaglutide 2.4 mg | Weekly injection | ~12–15% |
| Zepbound | Tirzepatide | Weekly injection | ~15–21% |
| Victoza | Liraglutide 1.8 mg | Daily injection (for T2D) | Modest (~3%) |
For deeper comparisons, see our guides on Saxenda vs Victoza and Saxenda side effects.
Cost and Insurance
- List price is roughly $1,300 to $1,600 per month without insurance
- Novo Nordisk offers a savings card that may reduce monthly cost for commercially insured patients
- Most commercial insurance plans require prior authorization with documentation of BMI and a previous lifestyle program attempt
- Medicare typically does not cover anti-obesity medications, although coverage is evolving
- Patient assistance programs exist for those who meet income criteria
How to Get the Best Results
- Pair Saxenda with a moderate calorie deficit (about 500 kcal/day below maintenance)
- Prioritize protein at 1.2–1.6 g/kg body weight per day to preserve muscle
- Aim for 150 minutes of moderate aerobic activity weekly plus 2 sessions of resistance training
- Eat smaller, more frequent meals during the first month to manage nausea
- Limit very fatty meals, alcohol, and large portions — they amplify GI side effects
- Stay hydrated — at least 64 oz of water daily
- Track weight weekly and report stalls or significant plateaus to your clinician
- Review your diet and nutrition plan with a registered dietitian when possible
When Saxenda May Not Be Right
- Personal or family history of medullary thyroid carcinoma or MEN2
- History of pancreatitis
- Severe gastroparesis or untreated gastroesophageal reflux
- Pregnancy, planning pregnancy, or breastfeeding
- Severe gallbladder disease
- Eating disorders involving restriction or purging
- Active treatment with another GLP-1 receptor agonist
Stopping Saxenda
Saxenda is a chronic therapy. The SCALE Maintenance trial showed that people who stopped the drug regained much of the lost weight within a year, while those who continued maintained most of their loss. If you must stop — for cost, side effects, or pregnancy — work with your clinician on a structured maintenance plan including continued calorie monitoring, exercise, and possibly a different medication.
The Bottom Line
Saxenda (liraglutide 3.0 mg) is a daily GLP-1 injection that produces about 5 to 8 percent body weight loss over a year when paired with diet and exercise. It is FDA-approved for adults with BMI 30+ or 27+ with a weight-related condition, and uniquely among GLP-1 drugs is also approved for adolescents 12 to 17. Side effects are mostly mild GI symptoms during the 5-week dose escalation. Weekly GLP-1 options like Wegovy and Zepbound are generally more potent, but Saxenda remains a useful tool, especially when weekly drugs are unavailable, not tolerated, or contraindicated. Treat it as a long-term therapy paired with sustained lifestyle change.
For broader context, see our treatment options overview or read more about external resources at the NIDDK weight-management medications guide.
